

Satoshi Yoshihara

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6480743/publications.pdf>

Version: 2024-02-01

89
papers

2,502
citations

236833

25
h-index

206029

48
g-index

89
all docs

89
docs citations

89
times ranked

2815
citing authors

#	ARTICLE	IF	CITATIONS
1	Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 13885-13890.	3.3	505
2	Risk and prevention of graft failure in patients with preexisting donor-specific HLA antibodies undergoing unmanipulated haploidentical SCT. Bone Marrow Transplantation, 2012, 47, 508-515.	1.3	188
3	Bronchiolitis Obliterans Syndrome (BOS), Bronchiolitis Obliterans Organizing Pneumonia (BOOP), and Other Late-Onset Noninfectious Pulmonary Complications following Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2007, 13, 749-759.	2.0	170
4	Unmanipulated HLA 2-3 Antigen-Mismatched (Haploidentical) Stem Cell Transplantation Using Nonmyeloablative Conditioning. Biology of Blood and Marrow Transplantation, 2006, 12, 1073-1084.	2.0	119
5	Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line Treatment. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 353-360.e1.	0.2	89
6	Impaired physiological function and health-related QOL in patients before hematopoietic stem-cell transplantation. Supportive Care in Cancer, 2012, 20, 821-829.	1.0	69
7	Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) bone marrow transplantation using only pharmacological GVHD prophylaxis. Experimental Hematology, 2008, 36, 1-8.	0.2	63
8	WT1 Peptide-Based Immunotherapy for Patients with Lung Cancer: Report of Two Cases. Microbiology and Immunology, 2004, 48, 175-184.	0.7	62
9	Lower incidence of Bronchiolitis obliterans in allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning compared with myeloablative conditioning. Bone Marrow Transplantation, 2005, 35, 1195-1200.	1.3	60
10	Wilms Tumor gene WT1 peptide-based immunotherapy induced a minimal response in a patient with advanced therapy-resistant multiple myeloma. International Journal of Hematology, 2007, 86, 414-417.	0.7	55
11	Unmanipulated Haploidentical Reduced-Intensity Stem Cell Transplantation Using Fludarabine, Busulfan, Low-Dose Antithymocyte Globulin, and Steroids for Patients in Non-Complete Remission or at High Risk of Relapse: A Prospective Multicenter Phase I/II Study in Japan. Biology of Blood and Marrow Transplantation, 2015, 21, 1495-1505.	2.0	54
12	Gender differences in health-related quality of life, physical function and psychological status among patients in the early phase following allogeneic haematopoietic stem cell transplantation. Psycho-Oncology, 2013, 22, 1159-1166.	1.0	51
13	Posttransplant Hemophagocytic Lymphohistiocytosis Driven by Myeloid Cytokines and Vicious Cycles of T-Cell and Macrophage Activation in Humanized Mice. Frontiers in Immunology, 2019, 10, 186.	2.2	50
14	Th1-biased humoral immune responses against Wilms tumor gene WT1 product in the patients with hematopoietic malignancies. Leukemia, 2005, 19, 268-274.	3.3	49
15	The role of HLA antibodies in allogeneic SCT: is the "type-and-screen"™ strategy necessary not only for blood type but also for HLA?. Bone Marrow Transplantation, 2012, 47, 1499-1506.	1.3	49
16	Increased affinity for copper mediated by cysteine 111 in forms of mutant superoxide dismutase 1 linked to amyotrophic lateral sclerosis. Free Radical Biology and Medicine, 2007, 42, 1534-1542.	1.3	47
17	WT1 peptide vaccination combined with BCG-CWS is more efficient for tumor eradication than WT1 peptide vaccination alone. Cancer Immunology, Immunotherapy, 2004, 53, 617-624.	2.0	46
18	Antithymocyte globulin affects the occurrence of acute and chronic graft-versus-host disease after a reduced-intensity conditioning regimen by modulating mixed chimerism induction and immune reconstitution. Transplantation, 2003, 75, 2135-2144.	0.5	43

#	ARTICLE	IF	CITATIONS
19	Frequency of CD4+FOXP3+ regulatory T-cells at early stages after HLA-mismatched allogeneic hematopoietic SCT predicts the incidence of acute GVHD. <i>Bone Marrow Transplantation</i> , 2013, 48, 859-864.	1.3	39
20	Clonal evolution and clinical implications of genetic abnormalities in blastic transformation of chronic myeloid leukaemia. <i>Nature Communications</i> , 2021, 12, 2833.	5.8	39
21	Extramedullary Relapse of Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: An Easily Overlooked but Significant Pattern of Relapse. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1800-1807.	2.0	38
22	Successful treatment of life-threatening human herpesvirus-6 encephalitis with donor lymphocyte infusion in a patient who had undergone human leukocyte antigen-haploidentical nonmyeloablative stem cell transplantation. <i>Transplantation</i> , 2004, 77, 835-838.	0.5	36
23	Incidence and treatment strategy for disseminated adenovirus disease after haploidentical stem cell transplantation. <i>Annals of Hematology</i> , 2012, 91, 1305-1312.	0.8	34
24	Impact of the mobilization regimen and the harvesting technique on the granulocyte yield in healthy donors for granulocyte transfusion therapy. <i>Transfusion</i> , 2012, 52, 2646-2652.	0.8	32
25	Salvage haploidentical transplantation for graft failure using reduced-intensity conditioning. <i>Bone Marrow Transplantation</i> , 2012, 47, 369-373.	1.3	29
26	Irreversible neurological defects in the lower extremities after haploidentical stem cell transplantation: Possible association with nelarabine. <i>American Journal of Hematology</i> , 2013, 88, 853-857.	2.0	26
27	High complete response rate after allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning regimens in advanced malignant lymphoma. <i>Bone Marrow Transplantation</i> , 2003, 32, 131-137.	1.3	22
28	Incidence of extramedullary relapse after haploidentical SCT for advanced AML/myelodysplastic syndrome. <i>Bone Marrow Transplantation</i> , 2012, 47, 669-676.	1.3	21
29	Intrabone Marrow Transplantation of Unwashed Cord Blood Using Reduced-Intensity Conditioning Treatment: A Phase I Study. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 633-639.	2.0	19
30	Modeling Human Leukemia Immunotherapy in Humanized Mice. <i>EBioMedicine</i> , 2016, 10, 101-108.	2.7	19
31	Idiopathic thrombocytopenic purpura after influenza vaccination in a bone marrow transplantation recipient. <i>Bone Marrow Transplantation</i> , 2006, 38, 323-324.	1.3	18
32	Preferential expression of the vasoactive intestinal peptide (VIP) receptor VPAC1 in human cord blood-derived CD34+CD38 ^{low} cells: possible role of VIP as a growth-promoting factor for hematopoietic stem/progenitor cells. <i>Leukemia</i> , 2004, 18, 912-921.	3.3	17
33	Donor-derived HLA antibody production in patients undergoing SCT from HLA antibody-positive donors. <i>Bone Marrow Transplantation</i> , 2012, 47, 1338-1342.	1.3	17
34	Use of mycophenolate mofetil in patients received allogeneic hematopoietic stem cell transplantation in Japan. <i>International Journal of Hematology</i> , 2011, 93, 523-531.	0.7	16
35	Strategy for bone marrow transplantation in eculizumab-treated paroxysmal nocturnal hemoglobinuria. <i>International Journal of Hematology</i> , 2011, 94, 403-407.	0.7	16
36	Solitary right ventricle metastasis by renal cell carcinoma. <i>Journal of the American Society of Echocardiography</i> , 2004, 17, 397-398.	1.2	15

#	ARTICLE	IF	CITATIONS
37	Use of foscarnet for cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation from a related donor. <i>International Journal of Hematology</i> , 2010, 92, 351-359.	0.7	14
38	Update on granulocyte transfusions. <i>Current Opinion in Hematology</i> , 2016, 23, 55-60.	1.2	14
39	A Randomized Controlled Trial to Compare Once- versus Twice-Daily Filgrastim for Mobilization of Peripheral Blood Stem Cells from Healthy Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 408-413.	2.0	13
40	Soluble interleukin-2 receptor level on day 7 as a predictor of graft-versus-host disease after HLA-haploidentical stem cell transplantation using reduced-intensity conditioning. <i>International Journal of Hematology</i> , 2014, 99, 463-470.	0.7	13
41	Powerful Graft-Versus-Leukemia Effects Exerted by HLA-Haploidentical Grafts Engrafted with a Reduced-Intensity Regimen for Relapse Following Myeloablative HLA-Matched Transplantation. <i>Transplantation</i> , 2004, 78, 488-489.	0.5	12
42	Predictive value of interim FDG-PET/CT findings in patients with diffuse large B-cell lymphoma treated with R-CHOP. <i>Oncotarget</i> , 2019, 10, 5403-5411.	0.8	12
43	A case of immune recovery vitritis induced by donor leukocyte infusion for the treatment of cytomegalovirus retinitis. <i>European Journal of Haematology</i> , 2005, 75, 352-354.	1.1	10
44	Recovery from established graft-vs-host disease achieved by bone marrow transplantation from a third-party allogeneic donor. <i>Experimental Hematology</i> , 2008, 36, 1216-1225.	0.2	10
45	Early detection of cytomegalovirus-specific cytotoxic T lymphocytes against cytomegalovirus antigenemia in human leukocyte antigen haploidentical hematopoietic stem cell transplantation. <i>Annals of Hematology</i> , 2015, 94, 1707-1715.	0.8	10
46	A prospective multicenter phase II study of intrabone marrow transplantation of unwashed cord blood using reduced-intensity conditioning. <i>European Journal of Haematology</i> , 2018, 100, 335-343.	1.1	10
47	Safety and efficacy of amnion-derived mesenchymal stem cells (AM01) in patients with steroid-refractory acute graft-versus-host disease after allogeneic haematopoietic stem cell transplantation: a study protocol for a phase I/II Japanese trial. <i>BMJ Open</i> , 2019, 9, e026403.	0.8	10
48	Selective targeting of multiple myeloma cells with a monoclonal antibody recognizing the ubiquitous protein CD98 heavy chain. <i>Science Translational Medicine</i> , 2022, 14, eaax7706.	5.8	10
49	Separation of antileukemic effects from graft-versus-host disease in MHC-haploidentical murine bone marrow transplantation: participation of host immune cells. <i>International Journal of Hematology</i> , 2010, 91, 485-497.	0.7	9
50	Host Foxp3+CD4+ Regulatory T Cells Act as a Negative Regulator of Dendritic Cells in the Peritransplantation Period. <i>Journal of Immunology</i> , 2016, 196, 469-483.	0.4	9
51	Outcomes of ixazomib/lenalidomide/dexamethasone for multiple myeloma: A multicenter retrospective analysis. <i>European Journal of Haematology</i> , 2021, 106, 555-562.	1.1	9
52	Early evaluation of tumor response to 90Y-ibritumomab radioimmunotherapy in relapsed/refractory B cell non-Hodgkin lymphoma: what is the optimal timing for FDG-PET/CT?. <i>European Radiology</i> , 2019, 29, 3935-3944.	2.3	8
53	Expression of activated integrin $\beta 7$ in multiple myeloma patients. <i>International Journal of Hematology</i> , 2021, 114, 3-7.	0.7	8
54	A Clinically Applicable Prediction Model to Improve T Cell Collection in Chimeric Antigen Receptor T Cell Therapy. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 365.e1-365.e7.	0.6	8

#	ARTICLE	IF	CITATIONS
55	Molecular detection of AML1-MTG8-positive cells in peripheral blood from a patient with isolated extramedullary relapse of t(8;21) acute myeloid leukemia. <i>Leukemia</i> , 2009, 23, 424-426.	3.3	7
56	Allogeneic stem cell transplantation as treatment for heavily treated, refractory acute graft-versus-host disease after HLA-mismatched stem cell transplantation. <i>Experimental Hematology</i> , 2011, 39, 880-890.	0.2	7
57	Different mechanisms causing loss of mismatched human leukocyte antigens in relapsing t(6;11)(q27;q23) acute myeloid leukemia after haploidentical transplantation. <i>European Journal of Haematology</i> , 2012, 89, 497-500.	1.1	7
58	Feasibility of unmanipulated haploidentical stem cell transplantation using standard GVHD prophylaxis for HLA-homozygous patients. <i>International Journal of Hematology</i> , 2012, 96, 101-108.	0.7	7
59	Low incidence of HHV-6 reactivation in haploidentical hematopoietic stem cell transplantation with corticosteroid as graft-versus-host disease prophylaxis compared with cord blood transplantation. <i>Transplant Infectious Disease</i> , 2019, 21, e13073.	0.7	7
60	Successful treatment with nilotinib after imatinib failure in a CML patient with a four-way Ph chromosome translocation and point mutations in BCR/ABL gene. <i>International Journal of Hematology</i> , 2011, 93, 243-246.	0.7	6
61	Real-world effectiveness and safety analysis of carfilzomib+lenalidomide+dexamethasone and carfilzomib+dexamethasone in relapsed/refractory multiple myeloma: a multicenter retrospective analysis. <i>Therapeutic Advances in Hematology</i> , 2022, 13, 204062072211045.	1.1	6
62	Kinetics of Granulocyte Colony-Stimulating Factor in the Human Milk of a Nursing Donor Receiving Treatment for Mobilization of the Peripheral Blood Stem Cells. <i>Acta Haematologica</i> , 2007, 118, 176-177.	0.7	4
63	Durable remission of post-transplant relapsed FLT3-ITD AML in response to gilteritinib administration after a second transplant from the same donor. <i>International Journal of Hematology</i> , 2020, 112, 249-253.	0.7	4
64	T-cell lymphoma, B-cell lymphoma, and myelodysplastic syndrome harboring common mutations: Trilineage tumorigenesis from a common founder clone. <i>EJHaem</i> , 2022, 3, 211-214.	0.4	4
65	Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Rescued with a Second Allogeneic Stem Cell Transplantation from a Haploidentical Mother after Relapse following Cord Blood Transplantation. <i>International Journal of Hematology</i> , 2004, 80, 453-457.	0.7	3
66	Direct antiglobulin test-negative autoimmune hemolytic anemia associated with HLA-haploidentical stem cell transplantation. <i>International Journal of Hematology</i> , 2011, 93, 558-560.	0.7	3
67	Retrospective multi-center study of Adolescent and Young Adult (AYA) Multiple Myeloma in Kansai Myeloma Forum registry. <i>International Journal of Hematology</i> , 2020, 112, 435-438.	0.7	3
68	Allogeneic hematopoietic stem cell transplantation from a 2-HLA-haplotype-mismatched family donor for posttransplant relapse: a prospective phase I/II study. <i>Bone Marrow Transplantation</i> , 2021, 56, 70-83.	1.3	3
69	Treatment of severe life-threatening graft-versus-host disease by autologous peripheral blood stem cell transplantation using a nonmyeloablative preconditioning regimen. <i>Haematologica</i> , 2003, 88, ELT06.	1.7	3
70	Association between the pharmacokinetics of rabbit anti-thymocyte globulin and acute graft-versus-host disease in patients who received haploidentical hematopoietic stem cell transplantation. <i>International Journal of Hematology</i> , 2022, 116, 248-257.	0.7	3
71	Detection of donor-derived CMV-specific T cells in cerebrospinal fluid in a case of CMV meningoencephalitis after cord blood stem cell transplantation. <i>International Journal of Hematology</i> , 2013, 97, 287-290.	0.7	2
72	Spousal hematopoietic stem cell transplantation. <i>International Journal of Hematology</i> , 2017, 105, 646-657.	0.7	2

#	ARTICLE	IF	CITATIONS
73	Impact of the use of hydroxyethyl starch in granulocyte apheresis using Spectra Optia. <i>Transfusion Medicine</i> , 2021, 31, 365-370.	0.5	2
74	High Prevalence of PNH-phenotype Cells in Patients Who Received CD19-targeted CAR T-cell Therapy. <i>HemaSphere</i> , 2021, 5, e628.	1.2	2
75	Minimal residual disease assessment using EuroFlow in patients with relapsed/refractory multiple myeloma who received carfilzomib+lenalidomide+dexamethasone (KRD) therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e184.	0.2	1
76	Treatment strategy in a patient showing borderline features between plasmablastic lymphoma and plasmablastic myeloma harboring a 17p deletion. <i>Annals of Hematology</i> , 2020, 99, 1405-1407.	0.8	1
77	Feasibility of six cycles of lenalidomide-based triplet induction before stem cell collection for newly diagnosed transplant-eligible multiple myeloma. <i>Hematology</i> , 2021, 26, 388-392.	0.7	1
78	Minimal Residual Disease Assessment Using Euroflow-NGF in Patients with Multiple Myeloma Treated with a Combination of Carfilzomib, Lenalidomide, and Dexamethasone (KRD). <i>Blood</i> , 2019, 134, 3130-3130.	0.6	1
79	Aldehyde dehydrogenase activity in cryopreserved cord blood cells for quality assessment prior to transplantation. <i>Molecular Medicine Reports</i> , 2018, 18, 4530-4534.	1.1	1
80	Severe acute heart failure during or following cytokine release syndrome after CAR T-cell therapy. <i>Leukemia Research Reports</i> , 2022, , 100338.	0.2	1
81	Dasatinib-induced rapid regression and complete molecular remission of multiple subcutaneous tumours presenting as relapsed chronic myeloid leukaemia after cord blood transplantation. <i>Leukemia Research</i> , 2011, 35, 1658-1659.	0.4	0
82	Low Incidence of Human Herpesvirus 6 Reactivation in Unmanipulated HLA-Haploidentical Related Stem Cell Transplantation with Corticosteroid As Graft-Versus-Host Disease Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S160-S161.	2.0	0
83	Spousal Hematopoietic Stem Cell Transplantation for Post-Transplant Relapse/Rejection. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S158-S159.	2.0	0
84	Stem cell factor, GM-CSF, and IL-3-Transgenic humanized mice develop fatal hemophagocytic lymphohistiocytosis. <i>Experimental Hematology</i> , 2015, 43, S48.	0.2	0
85	MO23-2 Significance of maintenance therapies in symptomatic multiple myeloma patients with HDT/ASCT. <i>Annals of Oncology</i> , 2021, 32, S312.	0.6	0
86	Significance of maintenance therapy after HDT/ASCT in symptomatic multiple myeloma: A multicenter retrospective analysis in Kansai Myeloma Forum. <i>EJHaem</i> , 2021, 2, 765-773.	0.4	0
87	A Novel Regimen of Unmanipulated HLA-Haploidentical Transplantation Using a Small Dose of Anti-T-Lymphocyte Globulin for Patients in High Tumor Burden. <i>Blood</i> , 2012, 120, 4203-4203.	0.6	0
88	Prospective Comparison Study of Prognostic Value of MRD Detected By 8-Color MFC (EuroFlow-NGF) and NGS in Patients with Multiple Myeloma in ASCT Setting. <i>Blood</i> , 2021, 138, 3946-3946.	0.6	0
89	Abstract 10168: Association Between the Grade of Cytokine Release Syndrome and Cardiac Dysfunction After Chimeric Antigen Receptor T Cell Therapy for Diffuse Large B Cell Lymphoma Patients. <i>Circulation</i> , 2021, 144, .	1.6	0